21Shares Submits Revised Injective ETF Filing
21Shares has submitted to the U.S. SEC a revised filing for the 21Shares Injective ETF, an S-1/A amendment. The development is net positive for INJ. The ETF application has entered the amendment stage, indicating that the issuer is still moving forward with bringing the product to market. The market may interpret this as a step toward INJ entering an institutional-investment pathway narrative. For traders, the upside is mainly at the expectation level: in the short term, funds are likely to trade on sentiment around the “altcoin ETF expansion” theme. However, S-1/A does not equal approval. If the price rallies quickly, it’s more important to focus on whether volume is picking up and on the strength of support during any pullback.
Source: BlockBeats
#INJ
Figure 1: 21Shares submits revised Injective ETF filing · Partial screenshot of the source page
Image source: https://www.theblockbeats.info/flash/367952
21Shares has submitted to the U.S. SEC a revised filing for the 21Shares Injective ETF, an S-1/A amendment. The development is net positive for INJ. The ETF application has entered the amendment stage, indicating that the issuer is still moving forward with bringing the product to market. The market may interpret this as a step toward INJ entering an institutional-investment pathway narrative. For traders, the upside is mainly at the expectation level: in the short term, funds are likely to trade on sentiment around the “altcoin ETF expansion” theme. However, S-1/A does not equal approval. If the price rallies quickly, it’s more important to focus on whether volume is picking up and on the strength of support during any pullback.
Source: BlockBeats
#INJ
Figure 1: 21Shares submits revised Injective ETF filing · Partial screenshot of the source page
Image source: https://www.theblockbeats.info/flash/367952
